A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-α2B in patients with metastatic melanoma

Clinical Cancer Research

Volumn 8, Issue 10, 2002, Pages 3075-3081

  Atkins, Michael B ^a   Gollob, Jared A ^a   Sosman, Jeffrey A ^b   McDermott, David F ^a   Tutin, Linda ^a   Sorokin, Patricia ^b   Parker, Robert A ^a   Mier, James W ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CISPLATIN; DACARBAZINE; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; ONDANSETRON; TEMOZOLOMIDE; VINBLASTINE;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; APPENDICITIS; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER STAGING; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DRUG RESPONSE; DRUG TOLERANCE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART DISEASE; HEART INFARCTION; HEART TAMPONADE; HEART VENTRICLE ARRHYTHMIA; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; KIDNEY FAILURE; MALE; MELANOMA; METASTASIS; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CISPLATIN; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFUSIONS, INTRAVENOUS; INTERFERON ALFA-2B; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME; VINBLASTINE;

EID: 0036795194     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Atkins, M. B., Shet, A., and Sosman, J. A. IL-2 clinical applications: melanoma. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Biologic Therapy of Cancer Principles and Practice. Ed. 3, pp. 50-73. Philadelphia: J. B. Lippincott Company, 2000.
2. Legha, S. S., Ring, S., Eton, O., Bedikian, A., Plager, C., and Papadopoulos, N. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M. D. Anderson Cancer Center Experience. Cancer J. Sci. Am., 3: S9-S15, 1997.
3. Gollob, J. A., and Atkins, M. B. Melanoma: chemotherapy, cytokine therapies, and biochemotherapy. In: A. J. Sober and F. G. Haluska (eds.), Skin Cancer, Atlas of Clinical Oncology, pp. 253-279. Lewiston, NY: B. C. Decker, 2001.
4. Keilholz, U., Conradt, C., Legha, S. S., Khayat, D., Scheibenbogen, C., Thatcher, N., Goey, S. H., Gore, M., Dorval, T., Hancock, B., et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J. Clin. Oncol., 16: 2921-2929, 1998.
5. Allen, I. E., Kupelnick, B., Kumashiro, M., et al. Efficacy of interleukin-2 in the treatment of metastatic melanoma: systematic review and meta-analysis. Sel. Cancer Ther., 1: 168, 2000.
6. Eton, O., Legha, S., Bedikian, A., Lee, J. J., Buzaid, A. C., Hodges, C., Ring, S. E., Papadopoulos, N. E., Plager, C., East, M. J., Zhan, F., and Benjamin, R. S. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a Phase III randomized trial. J. Clin. Oncol., 20: 2045-2052, 2002.
7. Keilholz, U., Goey, S. H., Punt, C. J., Proebstle, T. M., Salzmann, R., Scheibenbogen, C., Schadendorf, D., Lienard, D., Enk, A., Dummer, R., et al. Interferon-α2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J. Clin. Oncol., 15: 2579-2588, 1997.
8. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Seipp, C. A., Einhorn, J. H., White, D. E., and Steinberg, S. M. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon-α2b. J. Clin. Oncol., 17: 968-975, 1999.
9. Atkins, M. B. Overview of U. S. Intergroup Phase III trial of biochemotherapy in metastatic melanoma. Immune Enhancing Cytokines, 3: 8-10, 2001.
10. Atkins, M. B., O'Boyle, K. R., Sosman, J. A., Weiss, G. R., Margolin, K. A., Ernest, M. L., Kappler, K., Mier, J. W., Sparano, J. A., Fisher, R. I., et al. Multiinstitutional Phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J. Clin. Oncol., 12: 1553-1560, 1994.
11. Legha, S. S., Ring, S., Eton, O., Bedikian, A., Buzaid, A. C., Plager, C., and Papadopoulos, N. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon α, and interleukin-2 for patients with metastatic melanoma. J. Clin. Oncol., 16: 1752-1759, 1998.
12. Mitchell, M. S. Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J. Clin. Oncol., 7: 1701, 1989.
13. McDermott, D. F., Mier, J. W., Lawrence, D. P., van den Brink, M. R., Clancy, M. A., Rubin, K. M., and Atkins, M. B. A Phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, (CVD), interleukin-2 (IL-2) and interferon α-2b (IFN) in patients with metastatic melanoma. Clin. Cancer Res., 6: 2201-2208, 2000.
14. Ahmed, I. Malignant melanoma: prognostic indicators. Mayo Clin. Proc., 72: 356, 1997.
15. Patel, M., McCully, C., Godwin, K., and Balis, F. Plasma and cerebrospinal fluid pharmacokinetics of temozolomide. Proc. Am. Soc. Clin. Oncol., 14: 461a, 1995.
16. Friedman, H. S., Kerby, T., and Calvert, H. Temozolomide and treatment of malignant gliomas. Clin. Cancer Res., 6: 2585-2597, 2000.
17. Bleehen, N. M., Newlands, S. M., Thatcher, L. N., Selby, P., Valver, A. H., Rustin, G. J., Brampton, M., and Stevens, M. F. G. Cancer Reseach Campaign Phase II Trial of temozolomide in metastatic melanoma. J. Clin. Oncol., 3: 910-913, 1995.
18. Biasco, G., Pantaleo, M. A., and Casadei, S. Treatment of brain metastases of malignant melanoma with temozolomide. N. Engl. J. Med., 345: 621-622, 2001.
19. Middleton, M. R., Grob, J. J., Aaronson, N., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M., Aamdal, S., Cebon, J., Coates, A., et al. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic melanoma. J. Clin. Oncol., 18: 158-166, 2000.
20. Summers, U., Middleton, M. R., Calvert, H., Lee, S. M., Rutin, G., Newell, D. R., and Thatcher, N. Effect of temozolomide on central nervous system relapse in relapse in patients with advanced melanoma. Proc. Am. Soc. Clin. Oncol., 18: 531a, 1999.
21. Kaplan, E., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
22. Balch, C. M., Buzaid, A. C., Soong, S-J., Atkins, M. B., Cascinelli, N., Coit, D. G., Fleming, I. D., Gershenwald, J. E., Houghton, A., Jr., Kirkwood, J. M., McMasters, K. M., Mihm, M. F., Morton, D. L., Reintgen, D. S., Ross, M. I., Sober, A., Thompson, J. A., and Thompson, J. F. Final version of the American Joint Committee on Cancer staging system for cutaneous melanomas. J. Clin. Oncol., 19: 3635-3648, 2001.
23. O'Day, S. J., Boasberg, P. D., Kristedja, T. S., et al. Updated results of maintenance biotherapy with interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF) for patients with metastatic melanoma. Proc. Am. Soc. Clin. Oncol., 20: 352a, 2001.